Fidel Castro-Supported Lung Cancer Vaccine To Be Tested In U.S. Clinical Trials

Forbes - Tech 

Researchers Take First Steps Toward A Preventative Alzheimer's Pill FDA has approved an IND to conduct clinical trials with the Cuba-manufactured vaccine for non-small cell lung cancer. Today's death of Cuba's 90-year-old former totalitarian leader, Fidel Castro, is generating reflection of some of the positive aspects of science and healthcare to emerge under a Communist regime. But as the New York Times' Anthony DePalma wrote this morning, "His legacy in Cuba and elsewhere has been a mixed record of social progress and abject poverty, of racial equality and political persecution, of medical advances and a degree of misery comparable to the conditions that existed in Cuba when he entered Havana as a victorious guerrilla commander in 1959." One of those medical advances is a lung cancer vaccine called CIMAvax that is about to undergo clinical trials testing at Roswell Park Institute in Buffalo, New York. The immunotherapeutic isn't a vaccine in the conventional sense where the immune system is harnessed to attack the cancer itself.

Duplicate Docs Excel Report

Title
None found

Similar Docs  Excel Report  more

TitleSimilaritySource
None found